CJC-1295 NO DAC Community Reports
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/ipamorelin* · *peptides/cjc-1295-ipamorelin* · *peptides/sermorelin* · *peptides/tesamorelin*
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
CJC-1295 NO DAC Community Reports doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for CJC-1295 NO DAC Community Reports yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/ipamorelin* · *peptides/cjc-1295-ipamorelin* · *peptides/sermorelin* · *peptides/tesamorelin*
Who reports the strongest results
Users who run CJC-1295 no DAC in combination with ipamorelin, with consistent pre-sleep dosing, through a full 8–12 week cycle. Solo use of either CJC-1295 no DAC or ipamorelin produces markedly weaker results than the combination.
The highest-reporting category: people over 35 seeking body composition improvement, recovery enhancement, and sleep quality restoration — areas where natural GH output has meaningfully declined.
What the community actually says
Week 1–2: sleep and recovery come first
The early signal that the protocol is working: deeper, more restorative sleep, and vivid dreams beginning in week 1. These appear before any body composition change is visible. Improved morning energy follows. Community treats the vivid dream experience as the primary “it’s working” indicator.
Training recovery begins improving within the first 2–4 weeks — users note they can train more frequently without the usual accumulation of soreness.
Weeks 4–12: body composition shifts
- Subcutaneous fat reduction, particularly abdominal, visible around weeks 4–6
- Lean mass improvement: gradual, described as “quality” rather than rapid; meaningful at 8–12 weeks
- Skin quality and collagen improvements at 8+ weeks
Lab-anchored data (community 8-week self-experiment): IGF-1 rose from 168 to 287 ng/mL over 8 weeks on 250 mcg CJC-1295 no DAC + 250 mcg ipamorelin pre-sleep, 5 days/week.
Protocol as used by the community
Dose:
- CJC-1295 no DAC: 100–200 mcg per injection
- “Saturation dose” concept: community identifies ~100 mcg as the dose above which the GH pulse amplitude doesn’t significantly increase; most use 100–200 mcg
Injected simultaneously with ipamorelin (same syringe is fine — community confirms no incompatibility)
Timing:
- Pre-sleep dose is primary and most protected
- Optional fasted morning dose for a second daily pulse
- Minimum 2–3 hours fasted before injection (insulin blunts GH response)
Cycling: 8–12 weeks on → 4–8 weeks off. IGF-1 baseline testing before starting and during cycle is recommended by experienced users.
The no-DAC vs DAC question
Community consensus: no-DAC is preferred.
No-DAC’s 30-minute half-life creates discrete, pulsatile GH release that mimics the body’s natural GH secretion pattern. The long-acting DAC form (~8-day half-life) creates sustained GH elevation that disrupts pulsatility. Most community members consider pulsatility important for metabolic outcomes and receptor sensitivity.
For users who find multiple weekly injections burdensome, DAC has a following — but it’s the minority position.
Side effects
Mild profile:
- Water retention — most common; resolves in first 2–3 weeks
- Tingling in extremities — moderate incidence; GH-related
- Headache — occasional; dose-dependent
- Joint aches — higher doses or older users; fluid shifts from GH elevation
- Fatigue — occasional; early in cycles
No cortisol, prolactin, or hunger effects (those belong to GHRP-6 and similar).
Frequently asked questions (community version)
Can I inject CJC and ipamorelin in the same syringe? Yes — community broadly uses combined injections without compatibility issues reported.
Why combine with ipamorelin? Can’t I just use CJC alone? The GH pulse with the combination is 5–8× larger than with either alone. Community describes solo GHRH use as “leaving 80% on the table.”
How long before body composition changes? Don’t expect body composition results before week 4–6. Sleep and recovery improvements come first (weeks 1–2). Setting the right expectation timeline prevents premature dropout.
Cross-references
*peptides/ipamorelin*— the GHRP counterpart; almost always used together*peptides/cjc-1295-ipamorelin*— combination community reports (the full picture)*peptides/sermorelin*— alternative GHRH; weaker pulse, longer clinical track record*peptides/tesamorelin*— GHRH specialist for visceral fat reduction
Commercial note
CJC-1295 Without DAC is available through Alyve — use code OHM-15 at checkout for 15% off.